We will review the mechanisms of action and rationale for usage of TPO‐RAs, erythropoietin stimulating agents (ESAs), TXA, and other novel agents for ITP and acute hemorrhage in bloodless management (doses summarized in Table 1). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.